3.78
3.78 (0.03%)
As of Jan 14, 2022
Aldeyra Therapeutics, Inc. [ALDX]
Source:
Company Overview
We are a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases. Our lead product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease (DED) and allergic conjunctivitis (AC). We have additional product candidates in development for autoimmune diseases and other immune-mediated disease, as well as for proliferative vitreoretinopathy (PVR) and other retinal diseases.
Country | United States |
Headquarters | lexington, massachusetts |
Phone Number | 781-761-4904 |
Industry | manufacturing |
CEO | Todd C. Brady |
Website | www.aldeyra.com |